This story originally ran on Aug. 4.
Satoris this week said that it will distribute Rules-Based Medicine's panel of 189 protein biomarkers for neurology research.
RBM launched the service-based biomarker panel, called DiscoveryMAP, in June. The same month, Satoris launched three neurology biomarker panels of its own, one for differentiating patients with Alzheimer's disease from other forms of dementia, and two panels for plasma proteins associated with neurodegeneration and neuroinflammation
With this week's announcement, researchers and drug firms will be able to access four service-based biomarker panels from one source, Satoris said in a statement.
DiscoveryMAP's broad panel of analytes allows researchers to "understand their compound's efficacy, safety, and biological activity, and it is complementary to our existing biomarker panels," said Cris McReynolds, president and CEO of Satoris, in the statement.
Among the analytes contained on DiscoveryMAP are apoliprotein A1 and A2; C-reactive protein; various forms of interleukin; leptin; and von Willebrand factor, according to RBM.
According to Satoris, the 189-marker panel covers the "most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development … [and] can thus provide researchers with critical biological information plus leads for further study."
Satoris, based in Redwood City, Calif., bills itself as a diagnostic firm and has spent the past few years developing its AD panel, a 12-protein test. While the test is currently available only through research laboratories, McReynolds told ProteoMonitor last year that the company plans to eventually bring it to the clinic, which would require approval by the US Food and Drug Administration [see PM 08/07/08].
RBM, based in Austin, Texas, is a CLIA-certified biomarker testing laboratory.